Single-fraction lung SBRT achieved 100% estimated one-year local control in selected patients
Single-fraction SBRT achieved 100% estimated 12-month local control without grade ≥3 toxicity in a selected 49-patient cohort.
Single-fraction SBRT achieved 100% estimated 12-month local control without grade ≥3 toxicity in a selected 49-patient cohort.
Whole-lung, physical-dose and BED3 models performed similarly externally, with the best complete-model AUC only 0.684 and inadequate calibration.
Life-threatening bilateral pneumonitis with concurrent Pneumocystis infection developed three days after carbon-ion RT in a patient previously treated with nivolumab.
Planning on selected respiratory phases reduced lung, heart and esophageal dose, but the optimal phase differed by toxicity endpoint.
Eight of ten patients completed simulation-free single-fraction adaptive lung SBRT, with treatment taking a median 72 minutes.
4DCT ventilation predicted postoperative FEV1, FVC, and DLCO with concordance coefficients of 0.88–0.91 in the LIME trial.
Multimodal CT–MRI perfusion maps matched SPECT better than single-modality methods and reduced high-function lung dose in exploratory planning.
Early-treatment ventilation direction persisted to treatment completion in most photon- and proton-treated patients, with the prediction model explaining 89% of variation.
Preclinical lung studies support normal-tissue sparing, but uncertain biological thresholds, dose conformity, and respiratory motion still prevent clinical implementation.
ECHO generated consistent lung IMRT and VMAT plans while reducing active planner time by approximately 90 minutes per case.
Adding the first treatment CBCT improved response and survival prediction, while additional scans progressively reduced classification performance.
Pulmonary consolidation was common after single-fraction interstitial brachytherapy and frequently evolved into progressive retraction during the second year.
Thoracic AI contours showed strong geometric and dosimetric agreement, but physicians still rejected some heart and oesophageal contours.
Symptomatic grade ≥2 cardiac toxicity occurred in 8% after central or ultracentral lung SBRT, typically developing more than one year after treatment.
In mice, FLASH reduced acute chemokine and later macrophage-associated transcription versus conventional irradiation, without significantly reducing collagen deposition.